Abstract
Objectives: Radiohybrid prostate-specific membrane antigen (rhPSMA)-ligands are applicable as radiochemical twins for both diagnostic PET imaging and endoradiotherapy. Based on preliminary data as diagnostic ligand, the isomer rhPSMA-7.3 is a promising candidate for potential endoradiotherapy. The aim of this preclinical evaluation was to assess biodistribution, dosimetry and therapeutic efficacy of 19F/177Lu-rhPSMA-7.3 in comparison to the established therapeutic agent 177Lu-PSMA I&T (imaging & therapy). Methods: Biodistribution of 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T was performed in LNCaP tumor bearing SCID-mice after sacrifice at defined time points up to 7 days (n = 5). Organs and tumors were dissected, injected dose per gram (%ID/g) was determined and dosimetry calculations were performed using OLINDA/EXM1.0. The therapeutic efficacy of a single dose of 30 MBq 19F/177Lu-rhPSMA-7.3 (n = 7) was compared with 177Lu-PSMA I&T (n = 7) and control groups (n = 6-7) using C4-2 tumor bearing SCID-mice by evaluating tumor growth and survival over 6 weeks post treatment. Results: The biodistribution of 19F/177Lu-rhPSMA-7.3 revealed fast blood clearance (0.63 %ID/g at 1 h p.i.) and highest activity uptake in the spleen and kidneys, particularly in the first hour (33.25 %ID/g and 207.6 %ID/g, respectively at 1 h p.i.) indicating a renal excretion pathway. Compared with 177Lu-PSMA I&T, 19F/177Lu-rhPSMA-7.3 exhibited an initial (1 h) 2.6-fold higher tumor uptake in LNCaP xenografts and a longer retention (4.5 %ID/g vs. 0.9 %ID/g at 168 h). The tumor dose of 19F/177Lu-rhPSMA-7.3 was substantially higher (e.g. 7.47 µGy/MBq vs. 1.96 µGy/MBq at 200 mm3) compared with 177Lu-PSMA I&T. In most organs absorbed doses were higher for 177Lu-PSMA I&T. A single dose of 19F/177Lu-rhPSMA-7.3 showed a significantly higher tumor size reduction compared with 177Lu-PSMA I&T at the end of the experiment (P = 0.0167). At pre-defined termination of the experiment at 6 weeks 7/7 and 3/7 mice were still alive in the 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T groups compared to the control groups with 0/7 and 0/6 mice. Conclusion: 19F/177Lu-rhPSMA-7.3 can be considered a suitable candidate for clinical translation due to similar clearance kinetics and radiation dose to healthy organs, but superior tumor uptake and retention compared with 177Lu-PSMA I&T. Preliminary treatment experiments showed a favorable anti-tumor response.
- PET
- Radiobiology/Dosimetry
- Radionuclide Therapy
- 177Lu-radioligand therapy
- PSMA
- dosimetry
- preclinical biodistribution
- prostate cancer
- Copyright © 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
SNMMI members
Login to the site using your SNMMI member credentials
Individuals
Login as an individual user